Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Pili, R., . . . Denmeade, S. R. (2007). Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint.

Collins, Connie, Michael A. Carducci, Mario A. Eisenberger, John T. Isaacs, Alan W. Partin, Roberto Pili, Victoria J. Sinibaldi, Janet S. Walczak, and Samuel R. Denmeade. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 As Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response As a Primary Endpoint. 2007.

Collins, Connie, et al. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 As Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response As a Primary Endpoint. 2007.